| Multiple‐dose pharmacokinetics, pharmacodynamics, and safety of atorvastatin, an inhibitor of HMG‐CoA reductase, in healthy subjects DD Cilla Jr, LR Whitfield, DM Gibson, AJ Sedman, EL Posvar Clinical Pharmacology & Therapeutics 60 (6), 687-695, 1996 | 259 | 1996 |
| Pharmacodynamic effects and pharmacokinetics of atorvastatin after administration to normocholesterolemic subjects in the morning and evening DD Cilla Jr, DM Gibson, LR Whitfield, AJ Sedman The Journal of Clinical Pharmacology 36 (7), 604-609, 1996 | 137 | 1996 |
| Evaluation of an immunoseparation method for quantitative measurement of remnant-like particle-cholesterol in serum and plasma ET Leary, T Wang, DJ Baker, DD Cilla, J Zhong, GR Warnick, K Nakajima, ... Clinical chemistry 44 (12), 2490-2498, 1998 | 124 | 1998 |
| Tolerance and pharmacokinetics of single‐dose atorvastatin, a potent inhibitor of HMG‐CoA reductase, in healthy subjects EL Posvar, LL Radulovic, DD Cilla Jr, LR Whitfield, AJ Sedman The Journal of Clinical Pharmacology 36 (8), 728-731, 1996 | 123 | 1996 |
| Ratio of remnant-like particle-cholesterol to serum total triglycerides is an effective alternative to ultracentrifugal and electrophoretic methods in the diagnosis of familial … T Wang, K Nakajima, ET Leary, GR Warnick, JS Cohn, PN Hopkins, ... Clinical chemistry 45 (11), 1981-1987, 1999 | 53 | 1999 |
| Effects of regular and extended-release gemfibrozil on plasma lipoproteins and apolipoproteins in hypercholesterolemic patients with decreased HDL cholesterol levels EJ Schaefer, S Lamon-Fava, T Cole, DL Sprecher, DD Cilla Jr, ... Atherosclerosis 127 (1), 113-122, 1996 | 21 | 1996 |
| Single-and multiple-dose pharmacokinetics of CI-981, a potent HMG-CoA reductase inhibitor LR Whitfield, DD Cilla Jr, EL Posvar, AJ Sedman, DL Gibson Pharm Res 10 (suppl), S‐340, 1993 | 9 | 1993 |
| State-of-the-Art Review: Evaluation of the Clot Signature Analyzer as a Hemostasis Test in Healthy Volunteers Exposed to Low Doses of Aspirin T Igawa, R Kornhauser, DD Cilla, J O'Neal King, J Kambayashi Clinical and Applied Thrombosis/Hemostasis 5 (2), 117-121, 1999 | 7 | 1999 |
| Characteristics of dyslipidemia in intermittent claudication patients DD Cilla, T Wang, WP Forbes, K Nakajima Atherosclerosis 134 (1-2), 344-344, 1997 | 1 | 1997 |
| Comparison of different lipoprotein classes in assessing coronary heart disease risk. T Wang, ET Leary, DD Cilla, J Zhong, DD Baker, K Nakajima CLINICAL CHEMISTRY 46 (6), A101-A101, 2000 | | 2000 |
| Aspirin ingestion by healthy subjects increases ex vivo platelet retention on collagen-coated beads T Igawa, R Kornhauser, DD Cilla, JO King, JH Zhong, JI Kambayashi, ... THROMBOSIS AND HAEMOSTASIS, 363-363, 1999 | | 1999 |
| RLP-cholesterol to total triglyceride ratio is an efficient way to identify patients with type III hyperlipoproteinemia. T Wang, JS Cohn, PN Hopkins, DD Cilla, ET Leary, J Zhong, N Nakajima CLINICAL CHEMISTRY 45 (6), A18-A18, 1999 | | 1999 |
| Comparison of three methods of separation and quantification of serum lipoprotein remnants. D Cilla, D Baker, T Wang, K Nakajima CLINICAL CHEMISTRY 44, A81-A81, 1998 | | 1998 |
| Reference intervals of remnant-like-particles cholesterol (RLP-C) and triglyceride (RLP-TG) in fasting and non-fasting healthy volunteers using a commercial affinity gel method. DJ Baker, ET Leary, K Nakajima, D Cilla CLINICAL CHEMISTRY 43, 679-679, 1997 | | 1997 |
| Pharmaceutical industry careers in clinical research I Cohen, J Bender, D Cilla, M Texter, L McCormick American Journal of Hospital Pharmacy 47 (11), 2446-2448, 1990 | | 1990 |
